Monitoring and Treatment of Pediatric Patients with Fluvoxamine

Monitoring Requirements

• Close monitoring is essential when initiating treatment or changing doses, and patients should be assessed in person within 1 week of treatment initiation, with ongoing evaluation of symptoms, risk of suicide, possible adverse effects, adherence to treatment, and new or ongoing environmental stressors, as recommended by the American Academy of Pediatrics 1

Safety Considerations

• Fluvoxamine should not be used in children 6-12 years of age with depressive disorder in non-specialist settings, according to the National Institute for Health and Care Excellence 2
• Monitor closely for the emergence of adverse events, particularly suicidal ideation, as advised by the American Academy of Child and Adolescent Psychiatry 1

Duration of Treatment

• Maintenance treatment should continue for 6-12 months after full resolution of symptoms, with patients monitored monthly for 6-12 months after symptom resolution, as recommended by the American Academy of Pediatrics 1

Discontinuation

• The greatest risk of relapse occurs in the first 8-12 weeks after discontinuing medication, and close follow-up should be encouraged for at least 2-3 months after stopping the medication, as advised by the American Academy of Child and Adolescent Psychiatry 1

Special Considerations

• When switching from fluvoxamine to another SSRI, a cross-tapering approach is recommended to minimize withdrawal symptoms and avoid serotonin syndrome, according to the National Institute for Health and Care Excellence, although this fact is from Praxis Medical Insights, an alternative source is not available 3